A Phase 3 interventional study of Insulin Glargine (HOE901 - U300) and Insulin Glargine (HOE901 - U100) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 162 sites in 18 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-04-21.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment of the 175 interventional ones that give a count, is one of 14 that started in 2015, is one of 60 in phase 3, and was the 120th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 14 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,014 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 10th largest by enrollment of the 178 interventional ones that give a count, is one of 11 that started in 2015, is one of 80 in phase 3, and was the 127th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the non-inferiority of H0E901-U300 to Lantus, in change of glycated hemoglobin A1c (HbA1c).
Secondary Objectives:
To demonstrate the superiority of H0E901-U300 in comparison with Lantus in:
The study consisted of a 4-week screening period, a 26-week treatment period comparing HOE901-U300 to Lantus, and a 2-day safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
at screening visit:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
Drug: Insulin Glargine (HOE901 - U300) · Drug: Background therapy
Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
Drug: Insulin Glargine (HOE901 - U100) · Drug: Background therapy
Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
Also known as: Toujeo®
Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
Also known as: Lantus®
Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
Change in HbA1c From Baseline to Week 26
Adjusted least square (LS) means were obtained from analysis of covariance (ANCOVA) after multiple imputation of missing data including post baseline HbA1c data during the 26-week randomized period.
Time frame: Baseline, Week 26
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period
Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).
Time frame: Baseline up to Week 26
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period
Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).
Time frame: Baseline up to Week 26
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period
Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).
Time frame: Baseline up to Week 26
Percentage of Participants With HbA1c <7.5% or HbA1c <7% During 26-Week Randomized Period
Participants without any available HbA1c assessment at Week 26 were considered as non-responders in the analyses.
Time frame: Baseline up to Week 26
Percentage of Participants With HbA1c <7.5% or <7.0% at Week 26 and No Severe and/or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia During 26-Week Randomized Period
Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).
Time frame: Baseline up to Week 26
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
Adjusted LS means from multiple imputation approach including post baseline values during the 26-week randomized period.
Time frame: Baseline, Week 26
Change in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26
WHO-5 well-being index evaluates positive psychological well-being during the past 2 weeks and consists of 5 questions, each rated on a 6-point Likert scale from 0 (not present) to 5 (constantly present). Total raw score was transformed into a percentage score ranging from 0 (worst possible quality of life) to 100 (best possible quality of life).
Time frame: Baseline, Week 26
Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment
Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after Week 14) values were used to determine the requirement of rescue medication. Threshold values at Week 14: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.
Time frame: Baseline up to Week 26
Percentage of Participants With Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) During the 26 Weeks of Treatment
Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).
Time frame: Baseline up to Week 26
Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment
Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).
Time frame: Baseline up to Week 26
The study was conducted at 162 study centers across 18 countries. A total of 1515 participants were screened between 16 January 2015 and 14 October 2015, of whom 501 were screen failures.
| Milestone | HOE901-U300 | Lantus |
|---|---|---|
| Started | 508 | 506 |
| Treated (safety population) | 508 | 505 |
| Completed | 481 | 472 |
| Not completed | 27 | 34 |
| Withdrew: Adverse event | 6 | 6 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Poor compliance to protocol | 3 | 7 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Withdrew: Hypoglycemia | 1 | 0 |
| Withdrew: Other than specified above | 15 | 20 |
Adjusted least square (LS) means were obtained from analysis of covariance (ANCOVA) after multiple imputation of missing data including post baseline HbA1c data during the 26-week randomized period.
| percentage of hemoglobin | HOE901-U300 | Lantus |
|---|---|---|
| Change in HbA1c From Baseline to Week 26 | -0.89 ± 0.038 | -0.91 ± 0.042 |
Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period | 48.3 | 47.7 |
Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period | 20.2 | 22.5 |
Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period | 59.4 | 62.7 |
Participants without any available HbA1c assessment at Week 26 were considered as non-responders in the analyses.
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| HbA1c <7.5% | 60.6 | 58.9 |
| HbA1c <7.0% | 33.3 | 35.2 |
Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| HbA1c <7.5% | 26.4 | 21.5 |
| HbA1c <7.0% | 14.0 | 12.3 |
Adjusted LS means from multiple imputation approach including post baseline values during the 26-week randomized period.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 | -1.68 ± 0.122 | -1.77 ± 0.135 |
WHO-5 well-being index evaluates positive psychological well-being during the past 2 weeks and consists of 5 questions, each rated on a 6-point Likert scale from 0 (not present) to 5 (constantly present). Total raw score was transformed into a percentage score ranging from 0 (worst possible quality of life) to 100 (best possible quality of life).
| scores on a scale | HOE901-U300 | Lantus |
|---|---|---|
| Change in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26 | -1.16 ± 0.751 | 0.22 ± 0.758 |
Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after Week 14) values were used to determine the requirement of rescue medication. Threshold values at Week 14: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment | 3.7 | 2.6 |
Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Any hypoglycemia | 62.6 | 66.5 |
| Documented symptomatic hypoglycemia | 32.9 | 34.7 |
| Severe and/or confirmed hypoglycemia | 58.1 | 60.6 |
| Severe and/or confirmed hypoglycemia:<75 years age | 59.2 | 60.9 |
| Severe and/or confirmed hypoglycemia:≥75 years age | 54.8 | 59.4 |
Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).
| events per participant year | HOE901-U300 | Lantus |
|---|---|---|
| Any hypoglycemia | 6.06 | 7.74 |
| Documented symptomatic hypoglycemia | 1.85 | 2.56 |
| Severe and/or confirmed hypoglycemia | 5.17 | 6.36 |
Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).
| events per participant year | HOE901-U300 | Lantus |
|---|---|---|
| Any hypoglycemia:<75 years age | 6.44 | 7.85 |
| Any hypoglycemia:≥75 years age | 5.01 | 7.32 |
| Documented symptomatic hypoglycemia:<75 years age | 2.11 | 2.52 |
| Documented symptomatic hypoglycemia:≥75 years age | 1.12 | 2.71 |
| Severe and/or confirmed hypoglycemia:<75 years age | 5.43 | 6.37 |
| Severe and/or confirmed hypoglycemia:≥75 years age | 4.46 | 6.28 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 184) regardless of seriousness or relationship to IMP.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HOE901-U300 | 1/508 (0.2%) | 41/508 (8.1%) | 62/508 (12.2%) |
| Lantus | 0/505 (0%) | 34/505 (6.7%) | 64/505 (12.7%) |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| PneumoniaInfections and infestations | 1/508 | 3/505 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/508 | 1/505 |
| Atrial fibrillationCardiac disorders | 0/508 | 2/505 |
| Coronary artery diseaseCardiac disorders | 2/508 | 2/505 |
| PyelonephritisInfections and infestations | 0/508 | 2/505 |
| Hypertensive crisisVascular disorders | 1/508 | 2/505 |
| Acute myocardial infarctionCardiac disorders | 2/508 | 1/505 |
| Angina unstableCardiac disorders | 2/508 | 0/505 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/508 | 0/505 |
| Ischaemic strokeNervous system disorders | 2/508 | 0/505 |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| NasopharyngitisInfections and infestations | 37/508 | 38/505 |
| Upper respiratory tract infectionInfections and infestations | 27/508 | 28/505 |
Baseline population included all randomized participants.
| Age, Continuous(years) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 71.1 ± 4.9 | 70.8 ± 4.8 | 71.0 ± 4.9 |
| Sex: Female, Male(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Female | 258 | 229 | 487 |
| Male | 250 | 277 | 527 |
| Body Mass Index (BMI)(kg/m^2) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 30.9 ± 5.5 | 31.2 ± 5.7 | 31.1 ± 5.6 |
| Duration of Type 2 Diabetes(years) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 15.29 ± 8.17 | 15.35 ± 7.70 | 15.32 ± 7.93 |
| Baseline Glycated Hemoglobin A1c (HbA1c)(percentage of HbA1c) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 8.20 ± 0.91 | 8.22 ± 0.92 | 8.21 ± 0.91 |
| Randomization strata of insulin(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Insulin-naive | 166 | 165 | 331 |
| Insulin pre-treated | 342 | 341 | 683 |
| Age Group(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| <75 years of age | 373 | 400 | 773 |
| ≥75 years of age | 135 | 106 | 241 |
Showing the first 100 of 162 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2015, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine